FTRE Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FTRE from our risk checks.
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.90 |
| 52 Week High | US$41.02 |
| 52 Week Low | US$18.07 |
| Beta | 0 |
| 11 Month Change | 7.90% |
| 3 Month Change | 3.24% |
| 1 Year Change | -13.97% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.60% |
Recent News & Updates
Recent updates
Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16
Fortrea Holdings: Still Many Question Marks On This CRO Play
May 12Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08Fortrea Holdings' (NASDAQ:FTRE) Soft Earnings Are Actually Better Than They Appear
Nov 23Shareholder Returns
| FTRE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 11.7% | 2.6% | 2.6% |
| 1Y | -14.0% | 14.0% | 30.5% |
Return vs Industry: FTRE underperformed the US Life Sciences industry which returned 14% over the past year.
Return vs Market: FTRE underperformed the US Market which returned 30.5% over the past year.
Price Volatility
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FTRE has not had significant price volatility in the past 3 months.
Volatility Over Time: FTRE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
| FTRE fundamental statistics | |
|---|---|
| Market cap | US$2.14b |
| Earnings (TTM) | -US$215.50m |
| Revenue (TTM) | US$3.01b |
0.7x
P/S Ratio-9.9x
P/E RatioIs FTRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FTRE income statement (TTM) | |
|---|---|
| Revenue | US$3.01b |
| Cost of Revenue | US$2.56b |
| Gross Profit | US$456.60m |
| Other Expenses | US$672.10m |
| Earnings | -US$215.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 15.15% |
| Net Profit Margin | -7.15% |
| Debt/Equity Ratio | 76.9% |
How did FTRE perform over the long term?
See historical performance and comparison